EMA Authorised: Aumseqa (Aumolertinib mesilate) — SFL Pharmaceuticals Deutschland GmbH

View source ↗

Summary

The EMA authorised Aumseqa (aumolertinib mesilate) for non-small cell lung cancer, marking EU approval for this EGFR inhibitor with SFL Pharmaceuticals Deutschl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Aumseqa (Aumolertinib mesilate)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Non-Small-Cell Lung. MAH: SFL Pharmaceuticals Deutschland GmbH. Decision date: 12/02/2026